Firms eye development of targeted cancer drugs

11/13/2012 | GenomeWeb Daily News (free registration)

AstraZeneca has teamed up with Foundation Medicine to identify genetic mutations in cancer-related tumor genes that may help predict a person's response or resistance to targeted treatments. Under terms of the deal, Foundation will get right of first negotiation to develop diagnostic tests. The deal will allow AstraZeneca to "identify tumor-specific defects and alterations that can be used for patient segmentation," said Susan Galbraith, vice president and head of AstraZeneca's Oncology Innovative Medicines Unit.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA